In a phase I trial in 23 metastatic breast cancer patients and 7 hormone refractory prostate cancer patients (15, 17, 18), HER2 BATs were safe without dose limiting toxicities in the outpatient setting, and induced a partial remission in a HER2 negative patient for 7.5 months (15). Here, ERBB2 is linked to prostate carcinoma.